课题基金 / 基金详情

DIRECT ADMINISTRATIONOF ADGVVEGF121.10 W/VEGF121CDNA TO ISCH MYOCARADIUM

DIRECT ADMINISTRATIONOF ADGVVEGF121.10 W/VEGF121CDNA TO ISCH MYOCARADIUM
ADGVVEGF121.10 W/VEGF121CDNA 直接施用至 ISCH 心肌
批准号：
6114039
负责人：
RONALD G CRYSTAL
金额：
$7.95万
依托单位：
WEILL MEDICAL COLL OF CORNELL UNIV
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6114039
关键词：
blood vessels clinical research clinical trials collateral circulation gene therapy genetic transduction heart circulation heart function human subject human therapy evaluation myocardial ischemia /hypoxia transfection /expression vector vascular endothelial growth factors

项目摘要

项目成果

RONALD G CRYSTAL的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The focus of this protocol is to evaluate the adenoviral delivery of vascular endothelial growth factor (VEGF) directly to ischemnic myocardium. The objectives are: (1) to determine the dose-dependent safety/toxicity of direct administration of the vector AdGVVEGF121.10 to the ischemic myocardium, (2) to demonstrate whether direct administration of AdGVVEGF121.10 to the myocardium will induce growth of collateral blood vessels, improve coronary blood flow and improve cardiac function in the region of ischemia.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Ancillary SOURCE Study: Characterization of Small Airway Basal Cell Biology in Early COPD
Anti-eosinophil Gene Therapy for Eosinophilic Esophagitis
  • 批准号：
    10481279
  • 项目类别：
  • 资助金额：
    $30.0万
  • 财政年份：
    2022
  • 负责人：
    RONALD G CRYSTAL
  • 依托单位：
    ENYX THERAPEUTICS, LLC
Phase IA/IB Study of AAVrh.10hFXN Therapy to Treat the Cardiomyopathy of Friedreich's Ataxia
Phase IA/IB Study of AAVrh.10hFXN Therapy to Treat the Cardiomyopathy of Friedreich's Ataxia
海外基金